NovoMic

Company Overview

Snapshot

Founded in July 2014, NovoMic operates with 1–10 employees. The company was acquired by TRAISTMAN RADZIEJEWSKI FUNDACJA in January 2020, marking a significant exit in its operational history.

Business overview

NovoMic specializes in Health Tech & Life Sciences, developing Novokid, a 100% natural dry treatment for lice and nits. The company's patented technology utilizes vaporized plant-based ingredients, offering a chemical-free solution. Operating in the medical treatment and therapeutics sector, NovoMic serves global markets with a focus on children's health, providing a B2C product that is CE approved and certified by regulatory bodies.

Strategic signal

In January 2020, NovoMic was acquired by TRAISTMAN RADZIEJEWSKI FUNDACJA, transitioning its operational status to inactive. This acquisition signals a consolidation within the health tech sector, with NovoMic's innovative dry lice treatment technology now integrated into the acquiring entity's portfolio. For investors, this indicates a successful exit for NovoMic's earlier stakeholders and a strategic move by TRAISTMAN RADZIEJEWSKI FUNDACJA to expand its offerings in the medical products market.

Company Intelligence Q&A

What was a significant corporate event for NovoMic in January 2020?

In January 2020, NovoMic was acquired by TRAISTMAN RADZIEJEWSKI FUNDACJA. This transaction involved TRAISTMAN RADZIEJEWSKI FUNDACJA acquiring 90% of NovoMic's issued and outstanding capital stock from TechCare.

What was NovoMic's relationship with TechCare prior to the acquisition?

NovoMic merged with BreedIT in October 2016 to form TechCare and subsequently operated as a wholly owned subsidiary of TechCare until its acquisition in January 2020.

What strategic partnership did TechCare, NovoMic's parent company at the time, enter into in January 2019?

In January 2019, TechCare entered into a joint venture contract with China-Israel Biological Technology Co. Ltd. (CIB) to develop products for the Asian market, as reported by Calcalistech.

Who was appointed as the Chief Executive Officer of NovoMic in January 2019?

In January 2019, TechCare appointed Osnat Philipp, a former executive from Lumenis, P&G, and Teva Pharmaceuticals, as the Chief Executive Officer of NovoMic.

What type of product does NovoMic develop?

NovoMic develops Novokid, a 100% natural dry treatment for lice and nits, utilizing patented technology that vaporizes plant-based ingredients.